Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Scientific Reports|October 5, 2021
Exposure to food additive mixtures in 106,000 French adults from the NutriNet-Santé cohortEloi Chazelas, Nathalie Druesne-Pecollo, Younes Esseddik, et al.
European Journal of Epidemiology|April 9, 2026
Food colouring additives and cancer incidence in the NutriNet-Santé prospective cohortSanam Shah, Anaïs Hasenböhler, Guillaume Javaux, et al.
The Lancet. Diabetes & Endocrinology|April 25, 2024
Food additive emulsifiers and the risk of type 2 diabetes: analysis of data from the NutriNet-Santé prospective cohort studyClara Salame, Guillaume Javaux, Laury Sellem, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases InhibitorMustapha Haddach, Jerome Michaux, Michael K Schwaebe, et al.
Nature Communications|January 7, 2026
Associations between preservative food additives and type 2 diabetes incidence in the NutriNet-Santé prospective cohortAnaïs Hasenböhler, Guillaume Javaux, Marie Payen de la Garanderie, et al.
Diabetes Care|May 20, 2026
Food Coloring Additives and Incidence of Type 2 Diabetes in the NutriNet-Santé Prospective CohortSanam Shah, Anaïs Hasenböhler, Guillaume Javaux, et al.
Plos Medicine|April 8, 2025
Food additive mixtures and type 2 diabetes incidence: Results from the NutriNet-Santé prospective cohortMarie Payen de la Garanderie, Anaïs Hasenbohler, Nicolas Dechamp, et al.
Journal of Medicinal Chemistry|December 23, 2010
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancerFabrice Pierre, Peter C Chua, Sean E O'Brien, et al.
BMJ (Clinical Research Ed.)|September 6, 2023
Food additive emulsifiers and risk of cardiovascular disease in the NutriNet-Santé cohort: prospective cohort studyLaury Sellem, Bernard Srour, Guillaume Javaux, et al.
Molecular and Cellular Biochemistry|July 15, 2011
Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancerFabrice Pierre, Peter C Chua, Sean E O'Brien, et al.
Pageof 12